Neurodegenerative Diseases
Original Paper
Characteristic Motor and Nonmotor Symptoms Related to Quality of Life in Drug-Naïve Patients with Late-Onset Parkinson DiseasePark H.R.a, b · Youn J.a, b · Cho J.W.a, b · Oh E.-S.c · Kim J.S.a, b · Park S.d · Jang W.e · Park J.S.faDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, and bNeuroscience Center, Samsung Medical Center, Seoul, cDepartment of Neurology, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, dDepartment of Biostatistics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, eDepartment of Neurology, Gangneung Asan Hospital, College of Medicine, University of Ulsan, Gangneung, and fDepartment of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 30, 2017
Accepted: October 16, 2017
Published online: January 12, 2018
Issue release date: March 2018
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4
ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)
For additional information: https://www.karger.com/NDD
Abstract
Background/Aims: Unlike young-onset Parkinson disease (YOPD), characteristics of late-onset PD (LOPD) have not yet been clearly elucidated. We investigated characteristic features and symptoms related to quality of life (QoL) in LOPD patients. Methods: We recruited drug-naïve, early PD patients. The patient cohort was divided into 3 subgroups based on patient age at onset (AAO): the YOPD group (AAO <50 years), the middle-onset PD (MOPD) group, and the LOPD group (AAO ≥70 years). Using various scales for motor symptoms (MS) and non-MS (NMS) and QoL, we compared the clinical features and impact on QoL. Results: Of the 132 enrolled patients, 26 were in the YOPD group, 74 in the MOPD group, and 32 in the LOPD group. Among parkinsonian symptoms, patients in the LOPD group had a lower score on the Korean version of the Montreal Cognitive Assessment than the other groups. Logistic regression analysis showed genitourinary symptoms were related to the LOPD group. Linear regression analysis showed both MS and NMS were correlated with QoL in the MOPD group, but only NMS were correlated with QoL in the LOPD group. Particularly, anxiety and fatigue affected QoL in the LOPD group. Conclusion: LOPD patients showed different characteristic clinical features, and different symptoms were related with QoL for LOPD than YOPD and MOPD patients.
© 2018 S. Karger AG, Basel
Related Articles:
References
- Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA: Early- versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis 2010;19:1401-1408.
- Jang YK, Kwon H, Kim YJ, et al: Early- vs late-onset subcortical vascular cognitive impairment. Neurology 2016;86:527-534.
- Wickremaratchi MM, Ben-Shlomo Y, Morris HR: The effect of onset age on the clinical features of Parkinson's disease. Eur J Neurol 2009;16:450-456.
- Tang H, Huang J, Nie K, et al: Cognitive profile of Parkinson's disease patients: a comparative study between early-onset and late-onset Parkinson's disease. Int J Neurosci 2016;126:227-234.
- Spica V, Pekmezovic T, Svetel M, Kostic VS: Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. J Neurol 2013;260:131-137.
- Kostic V, Przedborski S, Flaster E, Sternic N: Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-205.
- Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N: Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
- Peretz C, Chillag-Talmor O, Linn S, et al: Parkinson's disease patients first treated at age 75 years or older: a comparative study. Parkinsonism Relat Disord 2014;20:69-74.
- Nagayama H, Hamamoto M, Nito C, Takagi S, Miyazaki T, Katayama Y: Initial symptoms of Parkinson's disease with elderly onset. Gerontology 2000;46:129-132.
- Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG: Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003;60:529-533.
- Wickremaratchi MM, Knipe MD, Sastry BS, et al: The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord 2011;26:457-463.
- Mehanna R, Moore S, Hou JG, Sarwar AI, Lai EC: Comparing clinical features of young onset, middle onset and late onset Parkinson's disease. Parkinsonism Relat Disord 2014;20:530-534.
- Post B, Speelman JD, de Haan RJ; CARPA Study Group: Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008;255:716-722.
- Knipe MD, Wickremaratchi MM, Wyatt-Haines E, Morris HR, Ben-Shlomo Y: Quality of life in young- compared with late-onset Parkinson's disease. Mov Disord 2011;26:2011-2018.
- Duncan GW, Khoo TK, Yarnall AJ, et al: Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord 2014;29:195-202.
- Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
- Wahlund LO, Barkhof F, Fazekas F, et al: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
- Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. 1967. Neurology 1998;50:318ff.
- Koh SB, Kim JW, Ma HI, et al: Validation of the Korean version of the nonmotor symptoms scale for Parkinson's disease. J Clin Neurol 2012;8:276-283.
- Brown RG, Dittner A, Findley L, Wessely SC: The Parkinson fatigue scale. Parkinsonism Relat Disord 2005;11:49-55.
- Chaudhuri KR, Pal S, DiMarco A, et al: The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-635.
- Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897.
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
- Jo SA, Park MH, Jo I, Ryu SH, Han C: Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population. Int J Geriatr Psychiatry 2007;22:218-223.
- Lee JY, Lee DW, Cho SJ, et al: Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008;21:104-110.
- Kwon DY, Kim JW, Ma HI, et al: Translation and validation of the Korean version of the 39-item Parkinson's disease questionnaire. J Clin Neurol 2013;9:26-31.
- Winikates J, Jankovic J: Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
- Youn J, Cho JW, Lee WY, Kim GM, Kim ST, Kim HT: Diffusion tensor imaging of freezing of gait in patients with white matter changes. Mov Disord 2012;27:760-764.
- Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
Article / Publication Details
Received: March 30, 2017
Accepted: October 16, 2017
Published online: January 12, 2018
Issue release date: March 2018
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 4
ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)
For additional information: https://www.karger.com/NDD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
